TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19457253

Group type: EXPERIMENTAL
Intervention: Tremelimumab alone (21 patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tremelimumab with autologous dendritic cells (6 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (before administration of tremelimumab)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with inflammatory and autoimmune toxicities
Number of subjects: 27
Study: 19458012

Group type: EXPERIMENTAL
Intervention: Whey protein (Whe-meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Casein (Cas-meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cod protein (Cod-meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gluten (Glu-meal)
Number of subjects: 12
Study: 19458352

Group type: COMPARATOR
Intervention: HLA-DQB1 locus
Number of subjects: 2072

Group type: COMPARATOR
Intervention: IL12A locus (rs6441286)
Number of subjects: 2072

Group type: COMPARATOR
Intervention: IL12A locus (rs574808)
Number of subjects: 2072

Group type: COMPARATOR
Intervention: IL12RB2 locus (rs3790567)
Number of subjects: 2072

Group type: COMPARATOR
Intervention: Five-allele haplotype in the 3' flank of IL12A
Number of subjects: 2072

Group type: COMPARATOR
Intervention: SNPs at the STAT4 locus
Number of subjects: 2072

Group type: COMPARATOR
Intervention: SNPs at the CTLA4 locus
Number of subjects: 2072
Study: 19459850

Group type: EXPERIMENTAL
Intervention: Vaccination with three peptides (TTK, LY6K, IMP-3) at 1 mg each, administered intradermally with 1 mL of incomplete Freund's adjuvant weekly for 5 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vaccination with three peptides (TTK, LY6K, IMP-3)
Number of subjects: 10
Study: 19461827

Group type: EXPERIMENTAL
Intervention: Bion microstimulator
Number of subjects: 9
Study: 19463408

Group type: EXPERIMENTAL
Intervention: Impella 2.5 system
Number of subjects: 20
Study: 19463409

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare-metal stent (historical control)
Number of subjects: 200
Study: 19463432

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté paclitaxel-eluting stent
Number of subjects: 1529
Study: 19463441

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-coated sirolimus-eluting stent (Excel) with 6-month dual antiplatelet therapy
Number of subjects: 2077
Study: 19464409

Group type: EXPERIMENTAL
Intervention: Linking inpatient clinical registry data to Medicare claims data
Number of subjects: 39539
Study: 19464412

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 48612
Study: 19466962

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times weekly for up to 16 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 50
Study: 19467341

Group type: EXPERIMENTAL
Intervention: F/S bid plus Zileuton 600 mg qid
Number of subjects: 22

Group type: COMPARATOR
Intervention: F/S bid
Number of subjects: 22
Study: 19470620

Group type: EXPERIMENTAL
Intervention: Cinacalcet (titrated from 30 mg twice daily to 90 mg four times daily during a titration phase of 2-16 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 17
Study: 19470631

Group type: EXPERIMENTAL
Intervention: Anastrozole, 1 mg, daily for 6 months
Number of subjects: 42
Study: 19470888

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein
Number of subjects: 99
Study: 19471019

Group type: EXPERIMENTAL
Intervention: Lenalidomide 30 mg/day once daily (days 1-21 every 28 days)
Number of subjects: 222
Study: 19474140

Group type: EXPERIMENTAL
Intervention: Baseline serum alpha-carotene concentrations
Number of subjects: 5450

Group type: EXPERIMENTAL
Intervention: Baseline lycopene concentrations
Number of subjects: 5450

Group type: EXPERIMENTAL
Intervention: Repeated measurements of alpha-carotene and beta-carotene
Number of subjects: 5450

Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 5450
Study: 19479077

Group type: EXPERIMENTAL
Intervention: GH treatment at maintenance dose
Number of subjects: 22

Group type: COMPARATOR
Intervention: GH withdrawal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GH resumption after withdrawal
Number of subjects: 22
Study: 19479315

Group type: EXPERIMENTAL
Intervention: Rest Tc-99m-mibi gated-SPECT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) Tc-99m-mibi gated-SPECT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no LDD)
Number of subjects: 40
Study: 19483644

Group type: EXPERIMENTAL
Intervention: PSA: 154-163 (155L) vaccination with Montanide ISA-51, 1 mg, given subcutaneously 7 times on weeks 0, 2, 4, 6, 10, 14, and 18.
Number of subjects: 5
Study: 19485285

Group type: EXPERIMENTAL
Intervention: Alpha-1 adrenergic blocker (A1AB) use
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pseudoexfoliation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 500

Group type: COMPARATOR
Intervention: Hypertension
Number of subjects: 500

Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 500
Study: 19486718

Group type: EXPERIMENTAL
Intervention: Risk score combining complete blood count and basic metabolic profile components
Number of subjects: 71921
Study: 19488737

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia clamp study (glucose at 11 mmol/l)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control tissues (liver and kidney)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between diabetic patients and normal volunteers
Number of subjects: 24
Study: 19491229

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSAs) for 12 months
Number of subjects: 112
Study: 19492578

Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (52 lean children)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Weight loss due to lifestyle intervention
Number of subjects: 319
Study: 19492661

Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Intradermal skin testing (ST)
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mL of a 1:1,000 dilution) intramuscularly
Number of subjects: 1456
Study: 19493369

Group type: EXPERIMENTAL
Intervention: Citalopram up to 60 mg/day for up to 14 weeks
Number of subjects: 2876
Study: 19494218

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant interleukin-1-receptor antagonist)
Number of subjects: 9
Study: 19496252

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled methacholine
Number of subjects: 0
Study: 19496761

Group type: EXPERIMENTAL
Intervention: General anesthesia with muscle relaxation
Number of subjects: 11101
Study: 19497063

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1

Group type: COMPARATOR
Intervention: Treatment options reviewed
Number of subjects: 1
Study: 19498019

Group type: EXPERIMENTAL
Intervention: Bortezomib once weekly (0.7-1.6 mg/m²; days 1, 8, 15, and 22; 35-day cycles)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bortezomib twice weekly (0.7-1.3 mg/m²; days 1, 4, 8, and 11; 21-day cycles)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both once-weekly and twice-weekly bortezomib
Number of subjects: 31
Study: 19502624

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction detectable at 1 week
Number of subjects: 42

Group type: COMPARATOR
Intervention: No detectable microvascular obstruction at any time point
Number of subjects: 42

Group type: COMPARATOR
Intervention: Microvascular obstruction detectable only at 2 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Microvascular obstruction detectable at both 2 days and 1 week
Number of subjects: 42
Study: 19502645

Group type: EXPERIMENTAL
Intervention: Prompt revascularization with intensive medical therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Insulin-sensitization therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin-provision therapy
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Revascularization in CABG stratum
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Medical therapy in CABG stratum
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin-provision group
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Insulin-sensitization group
Number of subjects: 2368
Study: 19504715

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30)
Number of subjects: 748
Study: 19505676

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV) implantation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (contralateral glaucomatous eyes receiving antiglaucoma medications)
Number of subjects: 41
Study: 19506188

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 321

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 321
Study: 19506189

Group type: EXPERIMENTAL
Intervention: 15-mL bottle
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 2.5-mL bottle
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 139
Study: 19506209

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 0
Study: 19506561

Group type: EXPERIMENTAL
Intervention: MIF gene expression in freshly isolated adipocytes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MIF gene expression in cultured preadipocytes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adipocyte MIF mRNA concentrations
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adipocyte diameter
Number of subjects: 34
Study: 19507171

Group type: EXPERIMENTAL
Intervention: GATC surveillance for anthracycline-induced cardiotoxicity
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: GATC surveillance for cisplatin-induced hearing impairment
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: GATC surveillance for codeine-induced mortality in breastfed infants
Number of subjects: 1836
Study: 19507806

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone (individualized doses), administered once daily.
Number of subjects: 388
Study: 19508731

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 19508997

Group type: EXPERIMENTAL
Intervention: Higher intake of DHA (>=64.0 mg/day)
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: Higher intake of EPA (>=42.3 mg/day)
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: Lower dietary glycaemic index (dGI <75.2)
Number of subjects: 2924

Group type: COMPARATOR
Intervention: Higher DHA intake in placebo group
Number of subjects: 2924
Study: 19509175

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pazopanib 300 mg twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pazopanib (various doses)
Number of subjects: 63
Study: 19515290

Group type: EXPERIMENTAL
Intervention: Daily alcohol use
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Days with sex
Number of subjects: 245
Study: 19515473

Group type: EXPERIMENTAL
Intervention: Home BP measured 3 times daily for 1 week using a validated oscillometric monitor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home BP measured during each third of the interdialytic interval.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory BP monitoring.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probing dry weight.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home BP compared to ambulatory BP.
Number of subjects: 0
Study: 19520420

Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m² followed by carboplatin AUC 5 mg/mL/minute every 4 weeks
Number of subjects: 58
Study: 19524963

Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 4 weeks or every 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous bisphosphonates (every 4 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 50
Study: 19527724

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a and ribavirin
Number of subjects: 260
Study: 19528536

Group type: EXPERIMENTAL
Intervention: Busulfan/fludarabine/antithymocyte globulin RIC regimen
Number of subjects: 47
Study: 19529780

Group type: EXPERIMENTAL
Intervention: BCG revaccination (BCG-BCG)
Number of subjects: 13

Group type: COMPARATOR
Intervention: BCG-MVA85A
Number of subjects: 13
Study: 19531247

Group type: EXPERIMENTAL
Intervention: Copy-number variation (CNV) in BMPR2
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (35 controls)
Number of subjects: 97
Study: 19535054

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Unit increase in APACHE II score
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Components of APACHE II (temperature, serum creatinine, Glasgow Coma Scale)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: ISS score
Number of subjects: 1019

Group type: COMPARATOR
Intervention: TRISS score
Number of subjects: 1019
Study: 19535099

Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 48
Study: 19536844

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study: 19539144

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1038
Study: 19539214

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 309
Study: 19540516

Group type: EXPERIMENTAL
Intervention: MKS3 mutations
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 3
Study: 19540952

Group type: EXPERIMENTAL
Intervention: H5N1 VN 2004 AA ca at 10(7.5) TCID(50)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: H5N1 VN 2004 AA ca at 10(6.7) TCID(50)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: H5N1 HK 2003 AA ca
Number of subjects: 59
Study: 19541818

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) patients with lower eGFR
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) patients
Number of subjects: 3612
Study: 19542735

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (ATG) 120 mg injections every 4-8 weeks
Number of subjects: 51
Study: 19545437

Group type: EXPERIMENTAL
Intervention: Collagen fleece-bound fibrin sealant
Number of subjects: 3098
Study: 19545857

Group type: EXPERIMENTAL
Intervention: Single subanesthetic dose of intravenous ketamine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thrice-weekly ketamine infusions over a 12-day period
Number of subjects: 26
Study: 19546056

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous pramlintide infusion (CSPI) at 9 microg/h with premeal bolus doses starting at 15 microg and titrated to 60 microg
Number of subjects: 11
Study: 19546477

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 92
Study: 19546476

Group type: EXPERIMENTAL
Intervention: 5-azacytidine and entinostat
Number of subjects: 30
Study: 19548294

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 15
Study: 19549699

Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) before PCI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) after successful PCI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Quantitative contrast stress echocardiography (CSE) in regions with restenosis after PCI
Number of subjects: 33
Study: 19549740

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (NAL-GLU, 150 microg/kg sc) followed by GnRH doses of 25, 75, 250, or 750 ng/kg iv every 4 h
Number of subjects: 19
Study: 19549995

Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing (53% overall)
Number of subjects: 3402

Group type: COMPARATOR
Intervention: No antibiotics prescribed (control group)
Number of subjects: 3402
Study: 19553641

Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib (600 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olaparib (10 mg daily for 2 of every 3 weeks)
Number of subjects: 60
Study: 19554094

Group type: EXPERIMENTAL
Intervention: Natural Eggshell Membrane (NEM) 500 mg once daily for four weeks (single-arm trial)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Natural Eggshell Membrane (NEM) 500 mg once daily for four weeks (double-arm trial)
Number of subjects: 39
Study: 19555842

Group type: EXPERIMENTAL
Intervention: Copeptin levels at presentation
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Combination of troponin T and copeptin
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Copeptin <14 pmol/l and troponin T < or =0.01 microg/l
Number of subjects: 487
Study: 19555845

Group type: EXPERIMENTAL
Intervention: Synergy Pocket Micro-pump device (CircuLite, Inc.)
Number of subjects: 17
Study: 19555921

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 26
Study: 19556425

Group type: EXPERIMENTAL
Intervention: Immunotherapy (autologous leukemia cells with GM-CSF-secreting K562 cells)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Immunotherapy-treated patients (28 patients)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Posttreatment induction of delayed-type hypersensitivity reactions
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Decrease in WT1 transcripts after first immunotherapy dose
Number of subjects: 54
Study: 19557149

Group type: EXPERIMENTAL
Intervention: Best practice implementation enhancement program
Number of subjects: 697
Study: 19561459

Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at 45 W/4 cm for 9 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at various power/diameter combinations (10 W/1 cm; 15 W/2 cm; 45 W/4 cm) for 9 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA) at 45 W/4 cm
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Saline-linked surface radiofrequency ablation (SLSRFA)
Number of subjects: 27
Study: 19562254

Group type: EXPERIMENTAL
Intervention: Erlotinib plus sirolimus (150 mg and 5 mg for patients not on concurrent CYP3A-inducing anti-epileptics; 450 mg and 10 mg for patients on EIAEDS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erlotinib plus sirolimus
Number of subjects: 32
Study: 19564755

Group type: EXPERIMENTAL
Intervention: Novel biomechanical device
Number of subjects: 19
Study: 19565495

Group type: EXPERIMENTAL
Intervention: Anti-TNF monoclonal antibody therapy (infliximab, adalimumab)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Anti-TNF monoclonal antibody therapy (etanercept)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exposure to infliximab versus etanercept
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exposure to adalimumab versus etanercept
Number of subjects: 69
Study: 19565560

Group type: EXPERIMENTAL
Intervention: PT-led classes
Number of subjects: 351

Group type: COMPARATOR
Intervention: CEI-led classes
Number of subjects: 351
Study: 19567517

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 7765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7765
Study: 19569973

Group type: EXPERIMENTAL
Intervention: 90 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 120 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 180 microg H5N1 A/Vietnam/1203/04 vaccine
Number of subjects: 75
Study: 19571722

Group type: EXPERIMENTAL
Intervention: Early sex (intercourse <42 days after circumcision)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: No early sex (control group)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Incomplete wound healing
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Complete wound healing (control group)
Number of subjects: 1246
Study: 19573495

Group type: EXPERIMENTAL
Intervention: 2 mg oral lorazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined measures for heterozygotes
Number of subjects: 36
Study: 19574030

Group type: EXPERIMENTAL
Intervention: SSRIs or venlafaxine
Number of subjects: 82
Study: 19576329

Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapies (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and beta-blocker use)
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Hospital discharge instructions
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: All guideline-recommended cardiac medications prescribed at discharge
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: In-hospital mortality risk
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Postdischarge mortality risk
Number of subjects: 48612
Study: 19576664

Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention in 29 obese children
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: SDS-BMI
Number of subjects: 89

Group type: COMPARATOR
Intervention: UMA
Number of subjects: 89

Group type: COMPARATOR
Intervention: Changes of WC
Number of subjects: 89

Group type: COMPARATOR
Intervention: Change of SDS-BMI and UMA
Number of subjects: 89
Study: 19577985

Group type: EXPERIMENTAL
Intervention: Expanded use of TAXUS Express Stent
Number of subjects: 7492

Group type: COMPARATOR
Intervention: Simple use of TAXUS Express Stent
Number of subjects: 7492
Study: 19581352

Group type: EXPERIMENTAL
Intervention: Patients with clinically significant pleural effusion (6.6% of total patients, 192 patients)
Number of subjects: 2892

Group type: EXPERIMENTAL
Intervention: Patients with pleural effusion (192 patients)
Number of subjects: 2892